NEW YORK (TheStreet) -- Nymox Pharmaceutical (NYMX - Get Report) shares are up by 0.39% to $2.55 on heavy volume in afternoon trading on Tuesday, after the biopharmaceutical company reported that its benign prostatic hyperplasia (BPH) treatment candidate met its primary endpoints in clinical trials.

The company said that its treatment, fexapotide, showed significantly better results when compared to the placebo treated control group while also minimizing side effects.

Nymox said that it intends to file for the necessary regulatory approvals following the test results.

The trial's most significant accomplishment was the lowering of the incidents of patients needing surgery within 24 months of being treated with fexapotide.

NYMX Chart NYMX data by YCharts